The ongoing debate continues

A message from Editor in Chief Marc B. Garnick, M.D.

Despite little evidence of benefit, most men over age 50 have had a prostate-specific antigen (PSA) test. And since 1992, the prostate cancer mortality rate in the United States has fallen by about 4% a year. But can we credit the falling death rate to PSA screening? Or are other factors, such as better-targeted treatments, playing a part?

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »